Tazidem Special Precautions

Prior to the administration, susceptibility to the drug should be tested to prevent manifestation of resistant bacteria, and the duration of therapy should be the minimum needed for the treatment.
Patients should be asked about their condition in order to predict the reaction such as shock and also their previous skin reaction should be tested.
First aid (against anaphylactic shock) should be prepared. After the administration, patient should be observed in a stable state. In the occurrence of allergic reaction, administration should be immediately discontinued. In severe case appropriate therapy such as epinephrine, hydrocortisone or antihistamine is instituted.
Prolonged use of this drug may result in overgrowth of insusceptible bacteria (Candida, Enterococcus).
Although this drug does not inhibit a renal function on the therapeutic dose, it is excreted by the kidney. Therefore, the dose should be appropriately reduced if patients have renal disorder. Neurologic secondary disease has been reported in patients without appropriate dose control.
Prior to this therapy, history of hypersensitivity to Ceftazidime, Cephalosporins, Penicillins and other drugs should be checked.
Like other broad spectrum Cephalosporins or Penicillins, tolerance to susceptible strain such as Enterobacter spp., Serratia spp. should be considered during this therapy.
Use in children: Safety has not been established in premature and newborn.
Use in elderly: In elderly patients, care should be taken in dose selection and patients should be carefully monitored.
1) Because elderly patients are more likely to have decreased renal function, this risk of adverse reactions may be greater.
2) Due to Vitamin K deficiency, bleeding tendency may occur.